florbetaben is an approved drug (EMA & FDA (2014))
Compound class:
Synthetic organic
Comment: Florbetaben F18 is the third PET (positron-emission tomography) reagent approved to identify amyloid-β (Aβ) as a diagnostic biomarker in the brains of patients with Alzheimer's disease (AD) [1]. Flutemetamol and florbetapir are the two other PET reagents approved for Aβ detection. These diagnostic tools allow direct and non-invasive in vivo visualisation and quantification of Aβ.
|
|
No information available. |
Summary of Clinical Use |
Florbetaben is approved as a tool to help identify the presence of amyloid-β (Aβ) as a diagnostic biomarker in the brains of patients with Alzheimer's disease (AD) [1]. |
External links |
For extended ADME data see the following: Electronic Medicines Compendium (eMC) European Medicines Agency (EMA) |